Eighty eight patients with hyperlipidaemia (81 white patients from South Africa and seven patients of mixed race from the West Cape area) were studied. Forty eight had adult familial hypercholesterolaemia, 16 had juvenile familial hypercholesterolaemia, and 24 had mixed hyperlipidaemia (increased cholesterol and triglycerides). They were interviewed and examined and their musculoskeletal manife...

The secondary hyperlipidaemias occur remarkably frequently, and the underlying cause of high serum lipid levels will often be missed if it is not actively sought. Diagnosis is important because the lipid abnormality responds to treatment of the primary disorder in most cases; notable exceptions to this, however, are the hyperlipidaemias associated with gout and chronic renal failure. The condit...

The occurrence of main coronary risk factors was assessed in the families of 211 men under age 56 from East Finland. Fifty men were survivors of a recent myocardial infarction, 55 had died of myocardial infarction, 53 suffered from uncomplicated angina, and 53 were healthy reference men. Familial hyperlipidaemia was twice and familial hypertension three times as common in case as in reference f...

BACKGROUND Postprandial hyperlipidaemia is known to be a high-risk factor for atherosclerotic disease because of rapid and lasting accumulations of triglyceride-rich lipoproteins and remnants. The Niemann-Pick C1-Like 1 (NPC1L1) protein acts as an intestinal cholesterol transporter and ezetimibe, which inhibits NPC1L1, has been used in patients with hypercholesterolaemia. We investigated effect...

The study was designed to evaluate the effect of silymarin alone on hyperlipidaemia within short interval (2 weeks) period on the lipid profile. 20 patients with hyperlipidaemia of various etiologies are involved in this study (13 males, 7 females) randomized into two groups, 10 patients received placebo and 10 patients received silymarin 600mg oral capsule once daily. The lipid profile was mea...

There is considerable evidence to suggest that the identification and treatment of dyslipidaemia will reduce the risk of premature CHD, i.e. before the age of 65. Diagnosis of the cause of raised plasma lipid levels will enable appropriate decisions to be taken with regard to management. The cornerstone of treatment is nutritional counselling and attention to other major risk factors for CHD, p...